Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 7,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasms Clear all
Active, not recruiting Not applicable Interventional

Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer

NCT03786354
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lymph Node Involvement, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy
Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Recruiting Phase 2 Interventional

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

NCT06185205
View directory record Official record
Conditions
Breast Cancer
Interventions
Accelerated partial breast irradiation
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
45 Years to 79 Years · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 12:02 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation

NCT00530751
View directory record Official record
Conditions
Breast Cancer
Interventions
counseling intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
7
States / cities
Canton, Ohio • Chardonr, Ohio • Mentor, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 30, 2026, 12:02 PM EDT
Terminated Phase 1 Interventional

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

NCT00346229
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, pegfilgrastim, lyso-thermosensitive liposomal doxorubicin(Thermodox), hyperthermia treatment
Biological · Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 30, 2026, 12:02 PM EDT
Terminated Phase 4 Interventional

Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy

NCT00699101
View directory record Official record
Conditions
Breast Cancer
Interventions
Conture Multi-Lumen Balloon
Device
Lead sponsor
SenoRx, Inc.
Industry
Eligibility
50 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 3 Interventional

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

NCT00003600
View directory record Official record
Conditions
Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, placebo
Biological · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
20
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

NCT03135171
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Pertuzumab, Tocilizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New Haven, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 4 Interventional Results available

RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF

NCT01035099
View directory record Official record
Conditions
Breast Cancer, Infertility
Interventions
Letrozole
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Not applicable Interventional

Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study

NCT05070299
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
Psychosexual Educational Partner Program (PEPP)
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 2 Interventional

Multi-Omics Study of the Effect and Mechanisms of Acupuncture on Psychoneurological Symptoms Among Breast Cancer Survivors

NCT05417451
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture
Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 30, 2026, 12:02 PM EDT
Not listed No phase listed Observational

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines

NCT03155802
View directory record Official record
Conditions
Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy, Biomarkers, Echocardiography
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 30, 2026, 12:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

CISPLATIN + AZD-1775 In Breast Cancer

NCT03012477
View directory record Official record
Conditions
Triple-negative Metastatic Breast Cancer
Interventions
Cisplatin, AZD1775
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 30, 2026, 12:02 PM EDT
Terminated Phase 2 Interventional Results available

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

NCT02774681
View directory record Official record
Conditions
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Cognitive Assessment, Palbociclib, Quality-of-Life Assessment, Trastuzumab
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 3 Interventional

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT00887536
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
522
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT03084536
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions
Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 30, 2026, 12:02 PM EDT
Terminated Early Phase 1 Interventional

An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer

NCT02380209
View directory record Official record
Conditions
Breast Cancer
Interventions
CEST MRI
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

NCT01597193
View directory record Official record
Conditions
Breast Cancer
Interventions
enzalutamide, anastrozole, exemestane, fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
17
States / cities
Aurora, Colorado • Enfield, Connecticut • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 30, 2026, 12:02 PM EDT
Active, not recruiting Phase 3 Interventional Results available

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

NCT00070564
View directory record Official record
Conditions
Breast Cancer
Interventions
pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
539
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib in Advanced Solid Malignancies

NCT01588821
View directory record Official record
Conditions
Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 30, 2026, 12:02 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer

NCT00087347
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
ferumoxytol, magnetic resonance imaging
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 30, 2026, 12:02 PM EDT
Terminated Phase 3 Interventional Results available

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

NCT00925548
View directory record Official record
Conditions
Breast Cancer
Interventions
Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 30, 2026, 12:02 PM EDT
Terminated No phase listed Observational

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

NCT05068726
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
18F Fluoroestradiol Radiopharmaceutical with PET/CT
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Flagstaff, Arizona • Cerritos, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

NCT00574587
View directory record Official record
Conditions
Breast Cancer
Interventions
Vorinostat, Paclitaxel, Trastuzumab, Doxorubicin, Cyclophosphamide, Surgery
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 30, 2026, 12:02 PM EDT